检索结果-南通市图书馆

Identification prognostic features related to sphingolipid metabolism and experimental validation of TRIM47 in hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

BIOCELL 2024年第4期48卷 639-651页

作者： JIAN TANG CHENQIANG ZHU YUN CHEN YUNLONG WU MING HE YI ZHOU MINGHUA XIE department of Intensive Care Unit The First People’s Hospital of Linping DistrictHangzhouChina department of Pharmacy The First People’s Hospital of Linping DistrictHangzhouChina

Background:The speciﬁc impact of sphingolipid metabolism on developing hepatocellular Carcinoma(HCC)remains *** study aims to explore the relationship between sphingolipid metabolism and HCC prognosis,immune response,and drug ***:Data were obtained from The Cancer Genome Atlas(TCGA)-Hepatocellular Carcinoma(LIHC)and Gene Expression Omnibus(GEO,GSE14520 datasets).47 sphingolipid metabolism genes were obtained from the Kyoto Encyclopedia of Genes and Genomes(KEGG)*** classifying HCC samples using the Non-negative Matrix Factorization(NMF)clustering method,differentially expressed genes were ***,8 risk genes were obtained by univariate analysis,survival random forest reduction and lasso *** expression of 8 risk genes was veriﬁed in ***:8 risk genes were used to construct the Sphingolipid score ***-Sphingolipid score predicted poor prognosis of HCC *** score was associated with immune checkpoints(IL-1B,TLR4,TGFB1,and IL-10),immune cells(Th2,Treg,MDSC,Neutrophil,Fibroblasts and macrophage),and MAPK *** the High-Sphingolipid score group,a signiﬁcantly higher proportion of patients with TP53(p53)mutations was signiﬁcantly higher(56%).Furthermore,patients with a high-Sphingolipid score were predicted to have a higher sensitivity to chemotherapy *** vitro validation showed that compared with normal liver cells LX-2,TRIM47,and S100A9 signiﬁcantly increased in liver cancer cells Hep G2,MHCC-97H,and Hep3B2.1-7,while SLC1A7,LPCAT1,and CFHR4 signiﬁcantly *** TRIM47 reduced the proliferation and promoted *** levels of ceramide synthesis-related indexes(CERS1,CERS6,CERS5,and SPTLC2)increased,and the ACER3 related to catalytic hydrolysis ***:We constructed a sphingolipid metabolism-related prognostic signature(Sphingolipid score)based on 8 risk ***47 may affect the development of liver cancer by regulating the relevant indicators of

关键词： Hepatocellular carcinoma Sphingolipid metabolism TRIM47 Prognosis

Effect of perioperative chemotherapy on resection of isolated pulmonary metastases from colorectal cancer:A single center experience

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Oncology 2024年第8期16卷 3457-3470页

作者： Zhao Gao Xuan Jin Ying-Chao Wu Shi-Jie Zhang Shi-Kai Wu Xin Wang department of Medical Oncology Peking University First HospitalBeijing 10000China department of General Surgery Peking University First HospitalBeijing 10000China department of Thoracic Surgery Peking University First HospitalBeijing 10000China

BACKGROUND Numerous studies have assessed surgical resection as a standard treatment option for patients with colorectal cancer(CRC)and resectable pulmonary metastases(PM).However,the role of perioperative chemotherapy after complete resection of isolated PM from patients with CRC patients remains *** hypothesize that perioperative chemotherapy does not provide significant survival benefits for patients undergoing resection of PM from *** To determine whether perioperative chemotherapy affects survival after radical resection of isolated PM from *** We retrospectively collected demographic,clinical,and pathologic data on patients who underwent radical surgery for isolated PM from *** survival(CSS)and disease-free survival were calculated using Kaplan-Meier ***-group differences were compared using the log-rank *** multivariate analysis,Cox regression was utilized when *** This study included 120 patients with a median age of 61.6 *** 5-year CSS rate was 78.2%,with 36.7% experiencing *** resection for isolated PM resulted in a 5-year CSS rate of 50.0% for second *** chemotherapy(P=0.079)did not enhance survival *** associated with improved survival included fewer metastatic lesions[hazard ratio(HR):2.51,P=0.045],longer disease-free intervals(HR:0.35,P=0.016),and wedge lung resections(HR:0.42,P=0.035).Multiple PM predicted higher recurrence risk(HR:2.22,P=0.022).The log-rank test showed no significant difference in CSS between single and repeated metastasectomy(P=0.92).CONCLUSION Perioperative chemotherapy shows no survival benefit post-PM resection in ***-free intervals and fewer metastatic lesions predict better *** metastasectomy is warranted for eligible patients.

关键词： Pulmonary metastasis Colorectal cancer Perioperative chemotherapy Survival Repeated pulmonary metastasectomy

Advanced cervix cancer patient with chemotherapy-induced grade IV myelosuppression achieved complete remission with cadonilimab:A case report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2024年第8期12卷 1510-1516页

作者： Rui Zhu Tian-Ze Chen Meng-Ting Sun Chun-Rong Zhu department of Oncology The First Affiliated Hospital of Soochow UniversitySuzhou 215000Jiangsu ProvinceChina department of Urology The First Affiliated Hospital of Soochow UniversitySuzhou 215000Jiangsu ProvinceChina

BACKGROUND The prognosis for patients with advanced metastatic cervix cancer(MCC)is poor,and this disease continues to pose a considerable therapeutic *** the administration of first-line regimens consisting of cisplatin,paclitaxel,and bevacizumab,survival rates for patients with metastasis remain *** emergence of bispecific antibodies(BsAbs)offers a novel treatment option for patients diagnosed with *** SUMMARY In this report,we present a patient with MCC who was treated with cadonilimab monotherapy at a dose of 6 mg/kg every two weeks after chemotherapy was proven to be *** patient exhibited a sustained complete response for a duration of 6 months,demonstrating an optimistic *** This case illustrates the considerable efficacy of cadonilimab for treating advanced ***,BsAb therapy is a promising strategy for effectively treating patients with advanced MCC and should be considered as an option when patients are intolerant to standard chemotherapy.

关键词： Cadonilimab Complete response Bispecific antibodies Recurrent or metastatic cervical cancer Programmed death protein 1 Cytotoxic T-lymphocyteassociated antigen-4 Case report

Azacitidine maintenance therapy for blastic plasmacytoid dendritic cell neoplasm allograft: A case report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2024年第1期12卷 136-141页

作者： Li-Li Tao Hui-Ting Wen Zi-Yi Wang Juan Cheng Li Zhao department of Hematology The First Clinical Medical CollegeLanzhou UniversityLanzhou 730000Gansu ProvinceChina department of Hematology The First Hospital of Lanzhou UniversityLanzhou 730000Gansu ProvinceChina

BACKGROUND Blastic plasmacytoid dendritic cell neoplasm(BPDCN)is a rare,highly invasive malignant *** is no universally accepted standard of care because of its rarity and the dearth of prospective *** is still challenging for some patients to achieve persistent clinical remission or cure,despite the success of allogeneic hematopoietic stem cell transplantation(allo-HSCT),indicating that there is still a significant recurrence *** report a case of prevention of BPDCN allograft recurrence by azacitidine maintenance therapy and review the relevant *** SUMMARY We report a 41-year-old man with BPDCN who was admitted to hospital due to skin sclerosis for>5 mo’*** was diagnosed by combined clinical assessment and laboratory *** diagnosis,the patients underwent induction consolidation chemotherapy to achieve the first complete remission,followed by bridging ***-transplantation,azacitidine(75 mg/m2 for 7 d)was administered as maintenance therapy,with repeat administration every 4–6 wk and appropriate extension of the chemotherapy *** 10 cycles,the patient has been disease free for 26 mo after *** assessments of bone marrow morphology,minimal residual disease,full donor chimerism,Epstein–Barr virus,and cytomegalovirus all yielded normal results with no abnormalities *** Azacitidine may be a safe and effective maintenance treatment for BPDCN following transplantation because there were no overt adverse events during the course of treatment.

关键词： Blastic plasmacytoid dendritic cell neoplasm Azacitidine Allogeneic hematopoietic stem cell transplantation Maintenance therapy Case report

Influence of blood glucose fluctuations on chemotherapy efficacy and safety in type 2 diabetes mellitus patients complicated with lung carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Diabetes 2024年第4期15卷 645-653页

作者： Tian-Zheng Fang Xian-Qiao Wu Ting-Qi Zhao Shan-Shan Wang Guo-Mei-Zhi Fu Qing-Long Wu Cheng-Wei Zhou department of Thoracic Surgery The First Affiliated Hospital of Ningbo UniversityNingbo 315020Zhejiang ProvinceChina department of Endocrine The First Affiliated Hospital of Ningbo UniversityNingbo 315020Zhejiang ProvinceChina department of Respiratory and Critical Care Medicine The First Affiliated Hospital of Ningbo UniversityNingbo 315020Zhejiang ProvinceChina

BACKGROUND Patients with type 2 diabetes mellitus(T2DM)have large fluctuations in blood glucose(BG),abnormal metabolic function and low immunity to varying degrees,which increases the risk of malignant tumor diseases and affects the efficacy of tumor *** hyperglycemia may have important therapeutic implications for cancer *** To clarify the influence of BG fluctuations on chemotherapy efficacy and safety in T2DM patients complicated with lung carcinoma(LC).METHODS The clinical data of 60 T2DM+LC patients who presented to the first Affiliated Hospital of Ningbo University between January 2019 and January 2021 were retrospectively *** patients underwent chemotherapy and were grouped as a control group(CG;normal BG fluctuation with a mean fluctuation<3.9 mmol/L)and an observation group(OG;high BG fluctuation with a mean fluctuation≥3.9 mmol/L)based on their BG fluctuations,with 30 cases *** indices,tumor markers,serum inflammatory cytokines and adverse reactions were comparatively *** correlation analysis was performed to analyze the correlation between BG fluctuations and tumor *** The fasting blood glucose and 2-hour postprandial blood glucose levels in the OG were notably elevated compared with those in the CG,together with markedly higher mean amplitude of glycemic excursions(MAGE),mean of daily differences,largest amplitude of glycemic excursions and standard deviation of blood glucose(P<0.05).In addition,the OG exhibited evidently higher levels of carbohydrate antigen 19-9,carbohydrate antigen 125,carcinoembryonic antigen,neuron-specific enolase,cytokeratin 19,tumor necrosis factor-α,interleukin-6,and highsensitivity C-reactive protein than the CG(P<0.05).Pearson analysis revealed a positive association of MAGE with serum tumor *** incidence of adverse reactions was significantly higher in the OG than in the CG(P<0.05).CONCLUSION The greater the BG fluctuation in LC patients after

关键词： Blood glucose fluctuation Type 2 diabetes mellitus Lung carcinoma Tumor markers

Risk of cardiovascular death in patients with hepatocellular carcinoma based on the Fine-Gray model

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Oncology 2024年第3期16卷 844-856页

作者： Yu-Liang Zhang Zi-Rong Liu Zhi Liu Yi Bai Hao Chi Da-Peng Chen Ya-Min Zhang Zi-Lin Cui first Central Clinical College Tianjin Medical UniversityTianjin 300070China department of Hepatobiliary Surgery Tianjin First Central HospitalSchool of MedicineNankai UniversityTianjin 300192China

BACKGROUND Hepatocellular carcinoma(HCC)is one of the most common types of cancers worldwide,ranking fifth among men and seventh among women,resulting in more than 7 million deaths *** the development of medical tech-nology,the 5-year survival rate of HCC patients can be increased to 70%.How-ever,HCC patients are often at increased risk of cardiovascular disease(CVD)death due to exposure to potentially cardiotoxic treatments compared with non-HCC ***,CVD and cancer have become major disease burdens ***,further research is needed to lessen the risk of CVD death in HCC patient *** This study was conducted on the basis of the Surveillance,Epidemiology,and End Results database and included HCC patients with a diagnosis period from 2010 to *** independent risk factors were identified using the Fine-Gray model.A nomograph was constructed to predict the CVM in HCC *** nomograph performance was measured using Harrell’s concordance index(C-index),calibration curve,receiver operating characteristic(ROC)curve,and area under the ROC curve(AUC)***,the net benefit was estimated via decision curve analysis(DCA).RESULTS The study included 21545 HCC patients,of whom 619 died of ***(5 cm:2.090(1.543-2.830),Pchemotherapy(none/unknown)[0.578(0.472-0.709),P<0.001]were independent risk factors for CVD death in HCC *** discrimination and calibration of the nomograph were *** C-index values for the training and validation sets were 0.736 and 0.665,*** AUC values of the ROC curves at 2,4,and 6 years were 0.702,0.725,0.740 in the training set and 0.697,0.710,0.744 in the validation set,*** calibration curves showed that the

关键词： Hepatocellular carcinoma Cardiovascular disease deaths Fine-Gray model Risk factor Nomograph Predict

Current landscape of preoperative neoadjuvant therapies for initial resectable colorectal cancer liver metastasis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2024年第7期30卷 663-672页

作者： Xiao-Fei Cheng Feng Zhao Dong Chen Fan-Long Liu department of Colorectal Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003Zhejiang ProvinceChina department of Radiation Oncology The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003Zhejiang ProvinceChina

Colorectal cancer liver metastasis(CRLM)presents a clinical challenge,and optimizing treatment strategies is crucial for improving patient *** resection,a key element in achieving prolonged survival,is often linked to a heightened risk of *** the potential benefits of preoperative neoadjuvant chemotherapy in managing resectable liver metastases,this approach has gained attention for its role in tumor downsizing,assessing biological behavior,and reducing the risk of postoperative ***,the use of neoadjuvant chemotherapy in initially resectable CRLM sparks ongoing *** balance between tumor reduction and the risk of hepatic injury,coupled with concerns about delaying surgery,necessitates a nuanced *** article explores recent research insights and draws upon the practical experiences at our center to address critical issues regarding considerations for initially resectable *** the criteria for patient selection and the judicious choice of neoadjuvant regimens are pivotal areas of *** the right balance between maximizing treatment efficacy and minimizing adverse effects is *** dynamic landscape of precision medicine is also reflected in the evolving role of gene testing,such as RAS/BRAF and PIK3CA,in tailoring neoadjuvant ***,the review emphasizes the need for a multidisciplinary approach to navigate the comp-lexities of *** technical expertise and biological insights is crucial in refining neoadjuvant *** management of progression following neoadjuvant chemotherapy requires a tailored approach,acknowledging the diverse biological behaviors that may *** conclusion,this review aims to provide a comprehensive perspective on the considerations,challenges,and advancements in the use of neoadjuvant chemotherapy for initially resectable *** combining evidencebased insights with practical experiences,we aspire to contribute

关键词： Neoadjuvant therapy Colorectal cancer liver metastasis Multidisciplinary teams Chemotherapeutic regimens Resectability criteria

Prognostic nutritional index in predicting survival of patients with gastric or gastroesophageal junction adenocarcinoma: A systematic review

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Oncology 2024年第2期16卷 514-526页

作者： Stylianos Fiflis Grigorios Christodoulidis Menelaos Papakonstantinou Alexandros Giakoustidis Stergos Koukias Paraskevi Roussos Marina Nektaria Kouliou Konstantinos Eleftherios Koumarelas Dimitrios Giakoustidis first department of Surgery General Hospital PapageorgiouThessaloniki 56429Greece department of General Surgery University Hospital of LarissaLarissa 41110Greece

BACKGROUND Gastric cancer is the third most common cause of cancer related death *** with or without chemotherapy is the most common approach with curative intent;however,the prognosis is poor as mortality rates remain *** indexes have been proposed in the past few years in order to estimate the survival of patients undergoing *** preoperative nutritional status of gastric cancer patients has recently gained attention as a factor that could affect the postoperative course and various indexes have been *** aim of this systematic review was to assess the role of the prognostic nutritional index(PNI)in predicting the survival of patients with gastric or gastroesophageal adenocarcinoma who underwent gastrectomy with curative *** To investigate the role of PNI in predicting the survival of patients with gastric or gastroesophageal junction *** A thorough literature search of PubMed and the Cochrane library was performed for studies comparing the overall survival(OS)of patients with gastric or gastroesophageal cancer after surgical resection depending on the preoperative PNI *** PRISMA algorithm was used in the screening process and finally 16 studies were included in this systematic *** review protocol was registered in the International Prospective Register of Systematic Reviews(PRO) RESULTS Sixteen studies involving 14551 patients with gastric or esophagogastric junction adenocarcinoma undergoing open or laparoscopic or robotic gastrectomy with or without adjuvant chemotherapy were included in this systematic *** patients were divided into high-and low-PNI groups according to cut-off values that were set according to previous reports or by using receiver operating characteristic curve analysis in each individual *** 5-year OS of patients in the low-PNI groups ranged between 39%and 70.6%,while in the high-PNI groups,it ranged between 54.9%and 95.8%.In most of the included st

关键词： Prognostic nutritional index Gastric adenocarcinoma Gastroesophageal junction cancer Prognosis Overall survival

GRIK1 promotes glioblastoma malignancy and is a novel prognostic factor of poor prognosis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Oncology Research 2024年第4期32卷 727-736页

作者： GUOQIANG HOU XINHANG XU WEIXING HU department of Neurosurgery First Affiliated Hospital of Nanjing Medical UniversityNanjingChina department of Neurosurgery Renji HospitalShanghai Jiao Tong UniversityShanghaiChina

Primary tumors of the central nervous system(CNS)are classified into over 100 different histological *** most common type of glioma is derived from astrocytes,and the most invasive glioblastoma(WHO IV)accounts for over 57%of these ***(GBM)is the most common and fatal tumor of the CNS,with strong growth and invasion capabilities,which makes complete surgical resection almost *** various treatment methods such as surgery,radiotherapy,and chemotherapy,glioma is still an incurable disease,and the median survival time of patients with GBM is shorter than 15 ***,molecular mechanisms of GBM characteristic invasive growth need to be clarified to improve the poor *** ionotropic receptor kainate type subunit 1(GRIK1)is essential for brain function and is involved in many mental and neurological ***,GRIK1’s pathogenic roles and mechanisms in GBM are still ***-nuclear RNA sequencing of primary and recurrent GBM samples revealed that GRIK1 expression was noticeably higher in the recurrent ***,immunohistochemical staining of an array of GBM samples showed that high levels of GRIK1 correlated with poor prognosis of GBM,consistent with The Cancer Genome Atlas *** of GRIK1 retarded GBM cells growth,migration,and *** together,these findings show that GRIK1 is a unique and important component in the development of GBM and may be considered as a biomarker for the diagnosis and therapy in individuals with GBM.

关键词： Glioblastoma GRIK1 Invasion Proliferation Prognosis